Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
UN Integrated Regional Information Networks - September 12, 2001
Health Minister Alphonsus Nwosu was reported as saying that he "would rather have the programme right and the deadline wrong, than vice versa," although he admitted that the generic drugs have not yet been received and the medication administration and tracking system has not been completely developed. The country's US $4 million programme will only provide drugs to 10,000 adults and 5,000 children, a "tiny fraction" of those infected. Indian generic drug maker Cipla has contracted with Nigeria to sell a three-drug combination for US $350 per year per patient. Participants will pay US $120, with the government subsidising the remaining cost.
Ranbaxy Laboratories, another India-based drug firm, is also being considered to supply drugs to the programme. Officials face several challenges in administering the programme, including fraudulent HIV claims from the nation's "notorious crime rings" that are trying to pose as patients to obtain the drugs and resell them on the black market, and NGOs representing people with HIV/AIDS who are "aggressively lobbying" the government to distribute the drugs through their organisations.
010912
IR010932
Copyright © 2001 - Integrated Regional Information Networks (IRIN). Reproduction of this article (other than one copy for personal reference) must be cleared through the Integrated Regional Information Network. .
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980 – 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .